Welcome to LookChem.com Sign In|Join Free
  • or
Benzenemethanol, 3,5-dichloro-a-ethenyl- is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

149946-93-0

Post Buying Request

149946-93-0 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

149946-93-0 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 149946-93-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,9,9,4 and 6 respectively; the second part has 2 digits, 9 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 149946-93:
(8*1)+(7*4)+(6*9)+(5*9)+(4*4)+(3*6)+(2*9)+(1*3)=190
190 % 10 = 0
So 149946-93-0 is a valid CAS Registry Number.

149946-93-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name 1-(3,5-dichlorophenyl)prop-2-en-1-ol

1.2 Other means of identification

Product number -
Other names 1-(3,5-dichloro-phenyl)-prop-2-en-1-ol

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:149946-93-0 SDS

149946-93-0Relevant academic research and scientific papers

Hydroxymethylation beyond Carbonylation: Enantioselective Iridium-Catalyzed Reductive Coupling of Formaldehyde with Allylic Acetates via Enantiotopic π-Facial Discrimination

Garza, Victoria J.,Krische, Michael J.

, p. 3655 - 3658 (2016)

Chiral iridium complexes modified by SEGPHOS catalyze the 2-propanol-mediated reductive coupling of branched allylic acetates 1a-1o with formaldehyde to form primary homoallylic alcohols 2a-2o with excellent control of regio- and enantioselectivity. These

Methods of treatment using an EP2 selective receptor agonist

-

Page/Page column 47, (2010/02/13)

The present invention relates to methods of treating pulmonary hypertension, facilitating joint fusion, facilitating tendon and ligament repair, reducing the occurrence of secondary fracture, treating avascular necrosis, facilitating cartilage repair, facilitating bone healing after limb transplantation, facilitating liver regeneration, facilitating wound healing, reducing the occurrence of gastric ulceration, treating hypertension, facilitating the growth of tooth enamel or finger or toe nails, treating glaucoma, treating ocular hypertension, and repairing damage caused by metastatic bone disease using an EP2 selective receptor agonist.

Prostaglandin agonists and their use to treat bone disorders

-

, (2008/06/13)

This invention relates to prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders including osteoporosis.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 149946-93-0